Inovio Ends Enrollment in Anal Dysplasia Study on VGX-3100 - Yahoo Finance
Inovio Ends Enrollment in Anal Dysplasia Study on VGX-3100 Yahoo Finance
Inovio Pharmaceuticals, Inc. INO announced that it has completed enrollment in a phase II study evaluating its lead HPV immunotherapy — VGX-3100 — for the ...
Comments
Post a Comment